reports
Genmab Commences Tender Offer for All Issued and Outstanding Common Sh...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to the previously...
Genmab Announces New Data Demonstrating Investigational Rinatabart Ses...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometria...
Millicom (Tigo) notice of third quarter 2025 results and video confere...
Millicom (Tigo) notice of third quarter 2025 results and video conference Millicom (Tigo) notice of third quarter 2025 results and video conference Luxembourg, October 16, 2025 – Millicom (NASDAQ: TIGO) expects to announce its third quarter 2025 results on November 6, 2025, via a press release. Millicom is planning to host a video conference for the global financial community on November 6, 2025, at 08:00 (New York) / 13:00 (London). Registration for the interactive event is required at the following . After registering, you will receive a confirmation email containing details about j...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarte...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,...
Millicom (Tigo) completes acquisition of Telefónica in Uruguay, streng...
Millicom (Tigo) completes acquisition of Telefónica in Uruguay, strengthening its regional footprint in South America Millicom (Tigo) completes acquisition of Telefónica in Uruguay, strengthening its regional footprint in South America Luxembourg, October 7, 2025 – Millicom International Cellular S.A. (“Millicom”) today announced that, following final approval from the Government of Uruguay, it has completed the acquisition of 100% of Telefónica Móviles del Uruguay S.A. (Movistar) for an enterprise value of USD 440 million. With this milestone transaction, Millicom officially enters the Ur...
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Acceleratin...
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, ...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2025 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share,...
Major Shareholder Announcement
Major Shareholder Announcement Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of September 19, 2025, Orbis Investment Management Limited through shares and ADRs, representing shares, controlled the voting rights to 3,230,732 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Invest...
Transactions with shares and linked securities in Genmab A/S made by m...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; September 9, 2025 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 09, 2025 – (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 36,464 shares at DKK 1,025.00,3,978 shares at DKK 1,050.00,497 shares at DKK 1,147.50,267 shares at DKK 1,155.00,691 shares at DKK 1,161.00,439 s...
Millicom (Tigo) subsidiary Telefónica Celular del Paraguay S.A.E. anno...
Millicom (Tigo) subsidiary Telefónica Celular del Paraguay S.A.E. announces its intent to partially redeem Senior Notes due 2027 Luxembourg, September 5, 2025 – Millicom’s subsidiary Telefónica Celular del Paraguay S.A.E (“Telecel Paraguay”) today announced its intent to redeem $150,000,000 aggregate principal amount of its 5.875% Senior Unsecured Notes due 2027 (the “Notes”) on September 15, 2024 (the “Redemption Date”). A notice of redemption will be sent to the holders of the Notes in accordance with the requirements of the indenture governing the Notes (the “Indenture”). Pursuant to the...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Eval...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd An...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, NY at 7:45 AM EDT (1:45 PM CEST) on September 9, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a co...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Se...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapyRegulatory decision supported by data from the Phase 1/2 RAINFOL™-01 trial showing encouraging responses in heavily pretreated EC patientsiRina-S continues to be ev...
Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Mer...
Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel Luxembourg, August 14, 2025 – Millicom (Tigo) today announced a key agreement with Empresas Públicas de Medellín (EPM) that advances its acquisition strategy in Colombia and unlocks a path toward the integration of Tigo-UNE and Colombia Telecomunicaciones (ColTel). Under the terms of the agreement: Millicom has committed to present an offer in EPM’s Law 226 sale process, subject to the terms published b...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 12, 2025 – (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million....
Genmab Announces Financial Results for the First Half of 2025
Genmab Announces Financial Results for the First Half of 2025 August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory FLRinatabart sesutecan (Rina-S®) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual MeetingData from over 40 abstracts highlighting the depth, breadth and strength of Genmab’s comprehensive epcori...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary ...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value
Millicom (Tigo) Q2 2025 Earnings Release
Millicom (Tigo) Q2 2025 Earnings Release Millicom (Tigo) Q2 2025 Earnings Release Luxembourg, August 7, 2025 – is pleased to announce its second quarter 2025 results. Please find below links to the Q2 2025 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Q2 2025 Highlights* Revenue $1.37 billion Operating profit $357 million, and record Adjusted EBITDA $641 million Net profit $676 million, including approximately $590 million net profit from infrastructure transactions Equity free cash flow $218 million Leverage of 2.18x, benefiting from one-time c...
Millicom (Tigo) declares $2.50 per share interim dividend to be paid i...
Millicom (Tigo) declares $2.50 per share interim dividend to be paid in two equal installments on October 15, 2025 and April 15, 2026 Luxembourg, August 6, 2025 – In line with the press release published on June 13, 2025, the Board of Directors of Millicom International Cellular S.A. (“Millicom”) approved the interim dividend of $2.50 per share, to be paid in two equal installments of $1.25 per share on October 15, 2025 and April 15, 2026. Other important dates and information relating to the Interim Dividend are as follows: First Installment Interim Dividend Payment First Installment Int...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.